Recordati S.p.A and Nymox Pharmaceutical Announce the Start of European Phase III Clinical Trial for NX-1207

Published: Feb 21, 2012

MILAN, Italy and HASBROUCK HEIGHTS, N.J., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Recordati (Borsa Italiana:REC.MI) and Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the start of activities aimed to the preparation of a European Phase III clinical trial for NX-1207, following the successful completion of a Scientific Advice meeting with the European Medicines Agency (EMA). NX-1207, Nymox's Phase III investigational drug, is currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH). The pivotal controlled clinical trial will assess the efficacy and safety of a single TRUS-guided intraprostatic injection of NX-1207 in patients with lower urinary tract symptoms (LUTS) associated with BPH not adequately controlled by medical therapy.

Back to news